BioAtla (BCAB) Profit After Tax (2020 - 2026)
BioAtla (BCAB) posted quarterly Profit After Tax of -$6.3 million for Q1 2026, up 58.63% year-over-year from -$4.0 million in Q1 2025, and up 35.16% quarter-over-quarter from -$9.8 million in Q4 2025.
BioAtla (BCAB) Profit After Tax (2020 - 2026) Analysis & Trends
BioAtla's Profit After Tax history runs 7 years deep, the most recent figure standing at -$6.3 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 58.63% year-over-year to -$6.3 million; the TTM figure through Mar 2026 stood at -$50.6 million (up 18.2% YoY), while the FY2025 annual figure was -$59.6 million, up 14.57% from the prior year.
- Profit After Tax for Q1 2026 stood at -$6.3 million, up from -$9.8 million in the prior quarter.
- The five-year high for Profit After Tax was -$6.3 million in Q1 2026, with the low at -$35.8 million in Q2 2023.
- The 5-year median for Profit After Tax is -$23.2 million (2024), against an average of -$21.5 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 68.23% in 2024, then slumped 49.05% in 2025.
- BioAtla's Profit After Tax stood at -$27.5 million in 2022, then increased by 2.24% to -$26.9 million in 2023, then soared by 44.72% to -$14.9 million in 2024, then surged by 34.26% to -$9.8 million in 2025, then soared by 35.16% to -$6.3 million in 2026.
- Business Quant data shows BCAB's Profit After Tax at -$6.3 million in Q1 2026, -$9.8 million in Q4 2025, and -$15.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | 452,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 452,000.00 |
| Mar 31, 2026 | -6.34 Mn |
| Dec 31, 2025 | -9.78 Mn |
| Sep 30, 2025 | -15.78 Mn |
| Jun 30, 2025 | -18.71 Mn |
| Mar 31, 2025 | -15.33 Mn |
| Dec 31, 2024 | -14.88 Mn |
| Sep 30, 2024 | -10.59 Mn |
| Jun 30, 2024 | -21.07 Mn |
| Mar 31, 2024 | -23.23 Mn |
| Dec 31, 2023 | -26.93 Mn |
| Sep 30, 2023 | -33.33 Mn |
| Jun 30, 2023 | -35.75 Mn |
| Mar 31, 2023 | -27.46 Mn |
| Dec 31, 2022 | -27.54 Mn |
| Sep 30, 2022 | -25.78 Mn |
| Jun 30, 2022 | -28.91 Mn |
| Mar 31, 2022 | -24.25 Mn |
| Dec 31, 2021 | -23.39 Mn |
| Sep 30, 2021 | -22.93 Mn |